These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 11451210

  • 1. Relevance of clinical pharmacological models for the evaluation of therapeutic dose range of an AT1-receptor antagonist.
    Brunner HR, Nussberger J.
    J Hypertens Suppl; 2001 Jun; 19(1):S15-20. PubMed ID: 11451210
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview.
    Brunner HR.
    J Hum Hypertens; 2002 May; 16 Suppl 2():S13-6. PubMed ID: 11967728
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
    Smith DH, Dubiel R, Jones M.
    Am J Cardiovasc Drugs; 2005 May; 5(1):41-50. PubMed ID: 15631537
    [Abstract] [Full Text] [Related]

  • 8. Effects of angiotensin receptor blockers on ambulatory plasma Renin activity in healthy, normal subjects during unrestricted sodium intake.
    Jones MR, Sealey JE, Laragh JH.
    Am J Hypertens; 2007 Aug; 20(8):907-16. PubMed ID: 17679042
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension.
    Chrysant SG, Marbury TC, Robinson TD.
    J Hum Hypertens; 2003 Jun; 17(6):425-32. PubMed ID: 12764406
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study.
    Barrios V, Boccanelli A, Ewald S, Girerd X, Heagerty A, Krzesinski JM, Lins R, Rodicio J, Stefenelli T, Woittiez A, Böhm M.
    Clin Drug Investig; 2007 Jun; 27(8):545-58. PubMed ID: 17638395
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Relationship between the frequency of blood pressure self-measurement and blood pressure reduction with antihypertensive therapy : results of the OLMETEL (OLMEsartan TELemonitoring blood pressure) study.
    Ewald S, vor dem Esche J, Uen S, Neikes F, Vetter H, Mengden T.
    Clin Drug Investig; 2006 Jun; 26(8):439-46. PubMed ID: 17163276
    [Abstract] [Full Text] [Related]

  • 16. Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements.
    Neutel J, Elliott WJ, Izzo J, Chen CL, Masonson H.
    J Clin Hypertens (Greenwich); 2002 Jun; 4(5):325-31. PubMed ID: 12368570
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effect of an olmesartan medoxomil-based treatment algorithm on systolic blood pressure in patients with stage 1 or 2 hypertension: a randomized, double-blind, placebo-controlled study.
    Kereiakes DJ, Maa JF, Shojaee A, Dubiel R.
    Am J Cardiovasc Drugs; 2010 Jun; 10(4):239-46. PubMed ID: 20653330
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.